Heramed Ltd (HMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Heramed Ltd (HMD) has a cash flow conversion efficiency ratio of -3.359x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.27 Million ≈ $-901.06K USD) by net assets (AU$379.12K ≈ $268.26K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HMD net asset quality index to measure how much of total assets are equity-financed.
Heramed Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Heramed Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Heramed Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Heramed Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Heramed Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VisDynamics Holdings Bhd
KLSE:0120
|
0.003x |
|
Legacy Iron Ore Ltd
AU:LCY
|
0.095x |
|
Zhejiang Yuancheng Landscape
SHG:603388
|
0.003x |
|
Farmer Bros. Co
NASDAQ:FARM
|
-0.125x |
|
Epitomee Medical Ltd
TA:EPIT
|
-0.416x |
|
Hochschild Mining plc
LSE:HOC
|
0.304x |
|
Hanwha Chemical Corp Pref
KO:009835
|
-0.030x |
|
D P Wires Limited
NSE:DPWIRES
|
0.208x |
Annual Cash Flow Conversion Efficiency for Heramed Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Heramed Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Heramed Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$1.72 Million ≈ $1.21 Million |
AU$-4.81 Million ≈ $-3.41 Million |
-2.807x | +76.49% |
| 2023-12-31 | AU$466.70K ≈ $330.22K |
AU$-5.57 Million ≈ $-3.94 Million |
-11.940x | -1249.49% |
| 2022-12-31 | AU$2.89 Million ≈ $2.05 Million |
AU$-2.56 Million ≈ $-1.81 Million |
-0.885x | +87.90% |
| 2021-12-31 | AU$441.88K ≈ $312.66K |
AU$-3.23 Million ≈ $-2.29 Million |
-7.314x | -422.60% |
| 2020-12-31 | AU$1.99 Million ≈ $1.41 Million |
AU$-2.78 Million ≈ $-1.97 Million |
-1.399x | -21.16% |
| 2019-12-31 | AU$2.39 Million ≈ $1.69 Million |
AU$-2.76 Million ≈ $-1.95 Million |
-1.155x | -183.85% |
| 2018-12-31 | AU$3.36 Million ≈ $2.37 Million |
AU$-1.37 Million ≈ $-966.34K |
-0.407x | +85.05% |
| 2017-12-31 | AU$201.88K ≈ $142.84K |
AU$-549.66K ≈ $-388.92K |
-2.723x | -71.31% |
| 2016-12-31 | AU$872.17K ≈ $617.12K |
AU$-1.39 Million ≈ $-980.81K |
-1.589x | -- |
About Heramed Ltd
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It also provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a remote fetal heart rate monitoring solution. The company has a collaboration agreement with Mayo Clinic for the … Read more